Navigation Links
Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology

SAN DIEGO, April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced three data presentations on etrasimod (APD334) at ASPET 2017 at Experimental Biology (EB).  The conference is taking place April 22-26 at McCormick Place Convention Center in Chicago, IL. 

The presentations encompass preclinical data highlighting the potent and selective immunomodulatory effects of etrasimod in inflammatory bowel disease (IBD), including ulcerative colitis (UC).

The following abstracts will be presented:

Title: Etrasimod, a Novel Sphingosine-1-Phosphate Receptor (S1PR1) Modulator, Lacks Functional Activity at S1P2 Receptors
Day of presentation: Sunday, April 23, 2017
Abstract Number: 6502
Poster Session Title: Cell Signaling and Cancer Therapeutics
Poster Board Number: D148
Location: McCormick Place Convention Center, Hall F

Title:  Etrasimod (APD334), an Oral, Next-Generation Sphingosine-1-Phosphate Receptor Modulator Inhibits the Development of Colitis in Lymphoid-Null Mice Injected with Colitogenic CD4+ T Cells
Day of presentation: Tuesday, April 25, 2017
Abstract Number: 6337
Poster Session Title: Drug Discovery and Development: Immunomodulation and Inflammation
Poster Board Number: D125
Location: McCormick Place Convention Center, Hall F

Title: Functional Activity of Etrasimod and a Diverse Panel of Sphingosine-1-Phosphate Receptor (S1PR1) Modulators at S1P4 Receptors
Day of presentation: Tuesday, April 25, 2017
Abstract Number: 6545
Poster Session Title: Drug Discovery and Development: Immunomodulation and Inflammation
Poster Board Number: D126
Location: McCormick Place Convention Center, Hall F

About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights.  Our three most advanced investigational clinical programs are ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune indications, and APD371 in Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; Arena's focus, and the potential of its programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial Officer


To view the original version on PR Newswire, visit:

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th
2. Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference
3. Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohns and Colitis Organisation - Inflammatory Bowel Diseases 2017
4. Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
5. How These Biotechs Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
6. Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
7. Arena Pharmaceuticals to Host Fourth Quarter and Full Year 2015 Financial Results and Corporate Update Conference Call and Webcast on Monday, February 29
8. Deloitte Corporate Finance LLC Advises The Marena Group, Inc. on its Recapitalization with The Riverside Company
9. Arena Helps Power IoT Revolution
10. Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin
11. Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference
Post Your Comments:
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):